Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Aug 29;10:2713-22.
doi: 10.2147/DDDT.S112852. eCollection 2016.

Clinical Study in Genital Herpes: Natural Gene-Eden-VIR/Novirin Versus Acyclovir, Valacyclovir, and Famciclovir

Free PMC article

Clinical Study in Genital Herpes: Natural Gene-Eden-VIR/Novirin Versus Acyclovir, Valacyclovir, and Famciclovir

Hanan Polansky et al. Drug Des Devel Ther. .
Free PMC article


Background: This paper reports the results of a clinical study that tested the effect of suppressive treatment with the botanical product Gene-Eden-VIR/Novirin on the number of genital herpes outbreaks. The results in this study were compared to those published in clinical studies of acyclovir, valacyclovir, and famciclovir.

Methods: The framework was a retrospective chart review. The population included 139 participants. The treatment was one to four capsules of Gene-Eden-VIR/Novirin per day. The duration of treatment was 2-48 months. The study included three controls recommended by the US Food and Drug Administration (FDA): baseline, no treatment, and dose response.

Results: The treatment decreased the number of outbreaks per year in 90.8% of the participants. The treatment also decreased the mean number of outbreaks per year from 7.27 and 5.5 in the control groups to 2.39 (P<0.0001 and P<0.001, respectively). The treated participants reported no adverse experiences. Out of the 15 tests that compared Gene-Eden-VIR/Novirin to the three drugs, Gene-Eden-VIR/Novirin had superior efficacy in eight tests, inferior efficacy in three tests, and comparable efficacy in four tests. Gene-Eden-VIR/Novirin also had superior safety.

Conclusion: The clinical study showed that the natural Gene-Eden-VIR/Novirin decreases the number of genital herpes outbreaks without any side effects. The study also showed that the clinical effects reported in this study are mostly better than those reported in the reviewed studies of acyclovir, valacyclovir, and famciclovir.

Keywords: acyclovir; famciclovir; genital herpes; natural treatment; outbreaks; valacyclovir.


Figure 1
Figure 1
Graphical presentations of the Gene-Eden-VIR/Novirin effect. Notes: Kaplan–Meier plots of time to first genital herpes recurrence in the current study from participants with a history of (A) at least one recurrence per year, (B) at least six recurrences per year, and (C) at least eight recurrences per year. (D) Percentage of participants versus frequency of recurrences.

Similar articles

See all similar articles

Cited by 3 articles


    1. Johnston C, Corey L. Current concepts for genital herpes simplex virus infection: diagnostics and pathogenesis of genital tract shedding. Clin Microbiol Rev. 2016;29(1):149–161. - PMC - PubMed
    1. Gupta R, Warren T, Wald A. Genital herpes. Lancet. 2007;370(9605):2127–2137. - PubMed
    1. Corey L, Adams HG, Brown ZA, Holmes KK. Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med. 1983;98(6):958–972. - PubMed
    1. Lebrun-Vignes B, Bouzamondo A, Dupuy A, Guillaume JC, Lechat P, Chosidow O. A meta-analysis to assess the efficacy of oral antiviral treatment to prevent genital herpes outbreaks. J Am Acad Dermatol. 2007;57(2):238–246. - PubMed
    1. Kukhanova MK, Korovina AN, Kochetkov SN. Human herpes simplex virus: life cycle and development of inhibitors. Biochemistry (Mosc) 2014;79(13):1635–1652. - PubMed

MeSH terms